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In 90% of people with erythropoietic protoporphyria (EPP), the disease results from the inheritance of a common hypomorphic FECH
allele, encoding ferrochelatase, in trans to a private deleterious FECHmutation. The activity of the resulting FECH enzyme falls below the
critical threshold of 35%, leading to the accumulation of free protoporphyrin IX (PPIX) in bone marrow erythroblasts and in red cells.
Themechanism of low expression involves a biallelic polymorphism (c.31548T>C) localized in intron 3. The 31548C allele increases
usage of the 30 cryptic splice site between exons 3 and 4, resulting in the transcription of an unstablemRNAwith a premature stop codon,
reducing the abundance of wild-type FECHmRNA, and finally reducing FECH activity. Through a candidate-sequence approach and an
antisense-oligonucleotide-tiling method, we identified a sequence that, when targeted by an antisense oligonucleotide (ASO-V1),
prevented usage of the cryptic splice site. In lymphoblastoid cell lines derived from symptomatic EPP subjects, transfection of
ASO-V1 reduced the usage of the cryptic splice site and efficiently redirected the splicing of intron 3 toward the physiological acceptor
site, thereby increasing the amount of functional FECH mRNA. Moreover, the administration of ASO-V1 into developing human
erythroblasts from an overtly EPP subject markedly increased the production of WT FECH mRNA and reduced the accumulation of
PPIX to a level similar to thatmeasured in asymptomatic EPP subjects. Thus, EPP is a paradigmaticMendelian disease inwhich the in vivo
correction of a common single splicing defect would improve the condition of most affected individuals.Erythropoietic protoporphyria (EPP, MIM 177000) is a rare
inherited disorder caused by the partial mitochondrial defi-
ciency of ferrochelatase (FECH, EC 4.99.1.1.), the last
enzyme in the heme biosynthesis pathway1 (See also
Balwani et al., 2012 in GeneReviews in theWeb Resources).
FECH is an inner mitochondrial membrane enzyme that
catalyzes the insertion of ferrous iron into free proto-
porphyrin IX (PPIX) to form heme. FECH deficiency in
medullar erythroid cells leads to overproduction and accu-
mulation of photoactive PPIX in erythrocytes and subse-
quently in the plasma, skin, bile, and feces.1 The most
common clinical manifestation of the disease is lifelong
acute photosensitivity of sun-exposed areas that first
appears in early childhood. Although it is generally a
benign disease, hepatic complications such as choleli-
thiasis or, in about 2% of cases, cirrhosis with rapidly fatal
liver disease, can occur.2–4 Cases of EPP have been reported
in Europe, the USA, China, and Japan. So far, no case of
EPP has been reported in individuals of African descent.
Constitutively, FECH undergoes alternative splicing of
exon 4 as a result of partial utilization of a cryptic intron
3 acceptor splice site located 63 bp upstream of the major
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The Aminclusion of 63 nucleotides of intron 3 about 20% of the
time. The aberrant mRNA contains an in-frame premature
stop codon (Figure 1) and is degraded by nonsense-medi-
ated mRNA decay.5–7 The hypomorphic C allele of a com-
mon intronic SNP, c.31548T>C (rs2272783, Figure 1), is
responsible for increasing the usage of the 63 bp cryptic
intron 3 acceptor splice site from 20% (for the T allele) to
60% (for the C allele), resulting in a reduction of FECH
activity. When, in combination with a severe FECH muta-
tion on the other allele, the overall FECH activity falls
below a critical threshold of about 35% of normal, PPIX
accumulates, and photosensitivity occurs.8,9Several studies
in the USA, Europe, and Asia have confirmed that this
mechanism is generally operative in EPP.10–15 According
to the French Centre of Porphyria database, 94% of French
EPP subjects show this striking inheritance pattern.
Because EPP is primarily a seasonal disease, and because
affected individuals present mainly non-life-threatening,
dermatological symptoms, integrative gene therapy is not
appropriate. Rather, correcting this single common
splicingmutation by antisense oligonucleotide (ASO) ther-
apy is an attractive strategy that should improve the condi-
tion of the majority of EPP subjects independently of theherches sur l’Inflammation, F-75018 Paris, France; 2Universite´ Paris Diderot,
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Figure 1. Schematic Representation of Exon 3–4 Splicing
of FECH
The c.315-48T>C transition modulates the splicing efficiency of a
constitutive cryptic acceptor splice site. 63 bp: position of the
cryptic acceptor splice site. (adapted from Gouya et al., 2002).nature of their FECH mutation. ASOs, which are generally
used for inhibiting gene expression, can also be used for
modulating pre-mRNA splicing by targeting splice sites or
by targeting positive or negative elements that affect
splice-site selection.16
In this study, we applied two strategies to identify ASOs
that repress the partial inclusion of intron 3 in FECH
mRNA: first, an ASO-tiling method to search for regulating
cis-acting elements residing within the 130 bp stretch
upstream of exon 4; and second, an orientated strategy
in which we used three ASOs targeting the putative
31548C-activated cryptic branch point, the cryptic
acceptor splice site, or both the cryptic splice site and the
31548C nucleotide (Figure 2A and Table 1). For all of
these experiments, we used locked nucleic acids (LNAs)
that demonstrate nuclease resistance and enhance affinity
for hybridization to complementary RNA.17 This class of
ASOs is highly effective for modifying pre-mRNA splicing
patterns.18 To investigate the effects of individual ASOs
on splicing, we constructed two FECH minigenes (FECH-
C-pcDNA3 and FECH-T-pcDNA3) comprising exon 3
(121 bp), a shortened intron 3 (300 bp, with either the
c.31548C or the c.31548T genotype) and exon 4medium at a final concentration of 30 mM. Twenty-four hours late
RNAplus reagent (MP Biomedical). Human-specific exon 3–4 FECH p
and aberrantly spliced mRNA, the PCR products were analyzed by ele
was measured with Image J Software. The migration positions of the n
product are indicated on the right. Ratios of the aberrantly spliced R
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ofectamine reagent (Invitrogen). Two days after transfec-
tion, we analyzed exon 3–4 FECH mRNA by RT-PCR with
a pair of human primers (Table S1). These primers did
not amplify the endogenous Cos7 FECH transcript
(Figure 2B). The extent of intron 3 inclusion was expressed
as the ratio of the intensity of the aberrantly spliced band
to the sum of the intensities of the aberrantly and correctly
spliced bands. FECH minigene transfection in Cos7 cells
recapitulated the splicing pattern as shown in lymphoblas-
toid cell lines (LBCL) of 31548C/C or T/T subjects.7 The
FECH-C-pcDNA3 minigene revealed a ratio of about
60%, and the FECH-T-pcDNA3 minigene one of 20%
(Figure 2B). For the ASO-tiling experiments, we cotrans-
fected the FECH-C-pcDNA3 minigene individually with
each of the ASOs (Figure S1A and Table S2; 13 ASOs, over-
lapping by 5 nt). None of the 13 LNA-ASOs used in the
initial ‘‘walk’’ along intron 3 reduced intron 3 retention
(Figure S1B). Only the ASO targeting position 45 to –63
(V1-LNA-ASO), which was obtained via the orientated
strategy and was complementary to a sequence including
the 31548 polymorphism and the 30 cryptic acceptor
splice site, reduced intron 3 inclusion to about 20% of
the total RNA, a level similar to the level obtained with
the FECH-T-pcDNA3 construction (Figure 2B). A dose-
response effect was already evident at 50 nM ASO concen-
tration,and was maximal at 125 nM (Figure 2B). To further
refine the targeting sequence, we microwalked around
the 45 position by using 18 additional 15-mer LNA-
ASOs (Figure S2A and Table S2). Again, none displayed
any effect, demonstrating that both the 31548 region
and the 63 acceptor splice site have to be targeted to
achieve the repression of intron 3 inclusion (Figure S2B
and S2C). Finally, we tested whether the splicing was sen-
sitive to the length of the ASO. We used eight additionalFigure 2. Repression of the Splicing of
Cryptic Exon 3–4 by a LNA-ASO Targeting
Both the Cryptic Acceptor Splice Site and
the 31548C Region
(A) Position of the LNA-ASOs targeting the
putative cryptic branch point (at posi-
tion 97 to 116), the cryptic acceptor
splice site (position 54 to 74), and the
31548 region (position 45 to 63).
Horizontal arrows represent the positions
of the PCR primers used for splicing anal-
ysis. Putative cryptic branch point:
(B) Inhibition of abnormal FECH splicing
by three LNA-ASOs. Cos7 cells were trans-
fected with 800 ng of plasmid and 2 ml of
Lipofectamine 2000 (Life Technologies).
Three hours later, the cells were trans-
fected with 50, 125, or 250 nM LNA and
2 ml of Lipofectamine 2000. Emetin (Sigma
Aldrich) was added simultaneously in the
r, the cells were harvested, and total RNA was extracted via the
rimers were used for qualitative PCR that amplified the correctly
ctrophoresis on a 3% agarose gel, and the density of the PCR bands
ormal exon 3–4 81 bp amplimer and the aberrantly spliced 144 bp
NA to the total RNA are indicated at the bottom.
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Table 1. LNA-ASOs Used in the Candidate-Sequence Approach
Position Sequence
45 to 63 50-gcEgcLtgEgaEatPttZt-30
54 to 74 50-gEaaZgtZttLtaLtcEatEa-30
97 to 116 50-aEaaLatZtcZcaPgcZgc-30
For each ASO in intron 3, the position corresponds to the distance of the final 50
and 30 ASO nucleotides from the first base of exon 4. The sequences are shown
on the complementary strand. LNA bases are as follows: ‘‘E’’ for adenine, ‘‘P’’
for guanine, ‘‘Z’’ for thymine, and ‘‘L’’ for cytosine.LNA-ASOs, which were one or two bases longer than V1-
LNA-ASO at either one or both extremities (Figure S2D
and Table S2). All these LNA-ASOs reduced intron 3 inclu-
sion, but none was more effective than the V1-LNA-ASO
(Figure S2E).
We further investigated whether reduction of intron 3
retention could also induce excess FECH mRNA produc-
tion. Therefore, we measured FECH splicing in lympho-
blastoid cell lines (LBCL) of an overt EPP-subject (subject
II1, FECH genotype c.709delT mutation/31548C) and
her asymptomatic brother (subject II3, FECH genotype
c.709delT mutation/31548T, Figure 3A). The optimal
concentration (125 nM) of V1-LNA-ASO or mock-ASO (a
complementary sequence of the ASO 45 to –63: 50-AAAA
CATTTCTCAGGCTGC-30) were transfected with lipofect-
amine reagent. Three hours after transfection, emetine
(Sigma-Aldrich) was added to the medium to block NMD.
Forty-eight hours after ASO transfection, endogenous
exon 3–4 splicing was analyzed with exon 3–4 RT-PCRA B
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mock-LNA-ASO without emetin. WT FECH RNA was analyzed by R
RNA. n ¼ 6 independent experiments. The Mann-Whitney statistica
The Am(Table 1; Figure 3B). As expected, intron 3 retention in
the LBCL of subject II3 (transfected with the mock ASO)
was about 25% lower than in the LBCL of subject II1
(abnormal mRNA/total mRNA ratio 0.30 versus 0.38, p ¼
0.0022; Figure 3B). Interestingly, when the LBCL of subject
II1 was transfected with V1-LNA-ASO, the proportion of
abnormally spliced RNA decreased from 0.38 to a level
similar to that measured in the asymptomatic II3 subject
(0.32 versus 0.30, not significant; Figure 3B). Wild-type
FECHmRNAwas thenmeasured by RT-qPCR using primers
specific to the wild-type exon 3–4 boundary (Table S1).
Twenty-four hours after transfection, normal FECH
mRNA was 30% more abundant in the LBCLs of the
asymptomatic (II3) than the overt (II1) subject
(Figure 3C),7 and 24 hr later, the normal mRNA of the cells
of the overt II1 subject treated with the V1-LNA-ASO
was 1.8- and 1.7-fold higher than that of the II1
mock-transfected and II3 -V1-LNA-ASO-transfected cells,
respectively (Figure 3C).
In summary, we identified a sequence at nucleo-
tides 45 to 63 that, when targeted by V1-LNA-ASO,
reduced intron 3 inclusion in LBCL with a 31548T/C
genotype to a level comparable to that of the 31548T/T
genotype and increased wild-type mRNA production in
the cells of an overt subject to a higher level than that
measured in an asymptomatic EPP subject. Taken together,
these results suggest that the V1-LNA-ASO has con-
siderable therapeutic potential. The sequence at posi-
tion 45 to 63 is intronic with regard to physiological
exon 3–4 splicing, but it becomes exonic when the 63
cryptic splice site is used. The mechanisms underlying                  48H
p=0.015
Figure 3. Restoration of WT FECHmRNA
Production in the LBCLs of EPP Subjects
Pedigree of the EPP-affected family. M in-
dicates the c.709delT deleterious FECH
mutation. T indicates the 31548T allele.
C indicates the 31548C allele. Subjects
I1 and II3 were asymptomatic carriers for
the c.709delT mutation (RefSeq accession
number NM_000140.3; FECH genotype
M/31548T), and subjects II1 and II2
were overt EPP subjects (FECH genotype
M/31548C). FC: FECH activity in nmol
of Zn-mesoporphyrin/mg of protein/hr.
(B) The LBCLs were transfected with
125 nM V1-LNA-ASO or mock-LNA-ASO
(43 to 65 sense sequence), and emetin
was added 24 hr later. Total RNA was ex-
tracted 48 hr after transfection. Splicing
of intron 3 to exon 4 was analyzed as in
Figure 2B. The ratios of the intensity of
the aberrantly spliced RT-PCR product to
the sum of the intensities of the aberrantly
and correctly spliced products are pre-
sented as box plots showing the median,
quartiles, and 90th and 10th percentiles.
n ¼ 6 experiments.
(C) Total RNA was extracted 24 and 48 hr
after transfection with V1-LNA-ASO or
T-qPCR with primers specific to the normally spliced exon 3–4
l test was used with Prism 4 software (Prism4 GraphPad software).
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Table 2. Clinical, Biochemical, and FECH Genotypic Data in Three EPP Subjects and One Control from Whom the CD34þ Erythroid
Precursors Were Extracted
Subject FECH Mutation 31548 Genotype Total Erythrocyte Protoporphyrins FECH Activity Phenotype
A c.1038T>G p.Tyr346Stop T/C 43 1.8 symptomatic
B c.10782A>G T/C 45 1.8 symptomatic
C c.1157A>C p.His386Pro T/T 2.5 2.4 asymptomatic
D WT T/T 1.5 5.6 asymptomatic
Total erythrocyte PPIX is expressed in mmol/l RBC. FECH activities are presented in nmol of Zn-Mesoporphyrin/mg of protein/hr. WT: wild-type. The FECH RefSeq
accession number is NM_000140.3.splicing redirection from the exon 3–4 boundary of the
cryptic to the physiological exon are complex and not
yet fully understood. Blocking exclusively either the 30
aberrant splice site (six ASOs: 50 to 64, 51 to 65,
52 to 66, 53 to 67, 61 to 75, and 54 to 74)
or the 31548 region (11 ASOs: 34 to 48, 35 to 49,
36 to 50, 37 to 51, 38 to 52, 39 to 53, 41
to 55, 45 to 59, 46 to 60, 47 to 61, and 48
to62) was not sufficient to restore proper splicing. In
the competition between the cryptic and the physiological
splice sites, redirection of splicing toward the physiological
site has to include blocking both the cryptic splice site and
the 31548 region, suggesting that this region might
include an exonic splicing enhancer (ESE) of cryptic
splicing or an intronic splicing inhibitor (ISI) of exon 3–4
splicing.
Because medullar erythroblasts are the relevant tissue to
be therapeutically targeted in EPP, we tested the V1-ASO
in differentiating CD34þ-derived, erythroid progenitors
isolated from the peripheral whole blood from two overt
EPP subjects (A and B), one asymptomatic subject (D),
and one control subject (C, Table 2). Our study was con-
ducted in accordance with the World Medical Association
Declaration of Helsinki ethical principles for medical
research involving human subjects and its subsequent
amendments. All subjects gave informed consent before
undergoing investigation. Overt subjects A and B had a
classical history of skin photosensitivity that began during
childhood, a high level of erythrocyte-free protoporphyrin,
and 25%–30% residual FECH activity in peripheral blood
mononuclear cells. The FECH genotypes of the overt
subjects consisted of a deleterious FECH mutation in trans
to the hypomorphic 31548C allele (Table 2). The non-
sense mutation of subject A most likely triggered mRNA
degradation, and the mutation in subject B resulted in
aberrant exon 10 splicing that conserved the correct
reading frame. The third subject (subject D) was an asymp-
tomatic EPP, and her FECH genotype consisted of a delete-
rious FECH nonsense mutation in trans to the 31548T
allele. Her erythrocyte PPIX levels were slightly above the
normal limit (X2), and her FECH activity in peripheral
bloodmononuclear cells was ~50%belownormal (Table 2).
For the oligonucleotide treatment, liposomal transfec-
tions of V1-LNA-ASO were ineffective because of their
high toxicity and poor transfection efficiency (data not614 The American Journal of Human Genetics 94, 611–617, April 3, 2shown). We therefore used a free-uptake method in
which morpholino-ASOs were added directly to the
culture medium at a final concentration of 45 mM (see
GeneReviews in Web Resources).19,20 R. Kole and col-
leagues developed the original method to direct mor-
pholino-ASOs to erythroid precursors in order to restore
human beta-globin gene expression in human IVS2-654
thalassemic erythroid cells.20 The authors also showed
that adding labeled morpholinos to the culture medium
from days 8 to 17 resulted in strong nuclear staining. The
morpholinos were prepared and purified by Gene Tools,
LLC (Philomath, USA). Two morpholino-ASOs, targeting
the sequence at position45 to63 in either the antisense
(PMO-V1) or the complementary sequence, respectively,
were used for the control mock oligonucleotide (PMO-
mock). The oligonucleotides were labeled with fluorescein
isithiocyanate (FITC).
The phenotype differentiation of erythroid cells was
monitored by flow cytometry (FACS Canto II, BD Bio-
sciences). Cells were stained with the relevant isotype or
antibodies (CD34PE 1/100 (A07776), CD36-FITC 1/100
(IM0766U), and CD71-FITC 1/100 (IM0483) from
Beckman Coulter and GPA-PE 1/50 (MHGLA04) from
Invitrogen). Hemoglobinization was monitored daily by
benzidine staining. Cell morphology was established after
May-Gru¨nwald-Giemsa staining of cytospin preparations
by light microscopy. Time-kinetic analysis of PPIX accu-
mulation was determined by flow cytometry at four stages
of differentiation: CFU (colony-forming unit) erythroblast
(CFU E), pro- and intermediate-erythroblast (pro-E, int E),
and late erythroblast (late E). These stages were established
on the basis of cell morphology (MGG coloration;
Figure S3) and the expression of the CD71 and GPA surface
markers, which correspond with the major stages of
development: CFU E (CD71lo, GPA), pro-E (CD71hi,
GPA/lo), int E (CD71hi, GPAhi), and late E (CD71lo,
GPAhi). PPIX accumulation in these cells was analyzed by
flow cytometry with an APC filter and the violet laser of
the Canto II (PPIX excitation, 405 nm; emission,
660 nm). Because of the limited number of cells available,
FECH activity could not be used for these experiments. WT
FECH mRNA and ALAS2 mRNA were quantified by
RT-qPCR (Table S1).
To determine the optimal conditions for ASO treat-
ments, we established a culture of CD34þ cells isolated014
Table 3. WT FECH and ALAS2 mRNA Quantifications in Primary
Cultures of EPP Erythroblasts
ALAS2 mRNA WT FECH mRNA
Subject A (M/C) mock 0.27 0.32
V1 0.40 0.51
Subject B (M/C) mock 0.86 0.96
V1 1.5 1.9
Control subject C (WT/T) mock 1 1
V1 0.75 0.73
Subject D (M/T) mock 1.1 1.1
V1 1.28 0.93
Subjects A, B, C, and D are described in Table 2. Abbreviations are as follows:
M, deleterious FECH mutation; WT, wild-type FECH; T, 31548T allele; and C,
31548C allele. Total RNA was extracted at the late E stage, and morpholino-
ASO targeting position45 to63 or mockmorpholino-ASOwas added seven
days after the CD34þ cells were isolated fromwhole blood. ALAS2 andWT FECH
RNA were analyzed by RT-qPCR with primers specific to the normal exon 3–4
spliced RNA of FECH. Both quantifications were normalized to two genes (B2M
[MIM 109700] and HPRT1 [MIM 308000]), and the results are expressed as a
percentage from the mock condition of subject C.from a healthy control. We assayed the time course of
FECH mRNA expression by RT-qPCR, and FECH mRNA
increased dramatically from the CFU E stage to the late E
stage (23-fold induction; Figure S4). Erythroid differentia-
tion was confirmed on the basis of cell morphology
(Figure S3), FACS analyses, and the progressive appearance
of hemoglobinized cells ranging from 0% at the CFU E
stage to >95% at the late E stage. Finally, morpholino
oligonucleotides were added before the induction of
heme production at the CFU E stage (after ~7 days in
culture) and maintained at the same concentration
(45 mM) until mature cells were obtained.N
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(all cytokines were from Miltenyi Biotec). Morpholino oligonucleot
CFU E stage (after ~7 days in culture) and maintained at the same con
analysis of PPIX accumulation was determined by flow cytometry at
graphs represent the ratios between the mean fluorescence intensity
in erythroid cells from two overt EPP subjects (subjects A and B), on
subject (subject D), who were each treated with PMO-V1 (triangles)
The AmNormal FECH and ALAS2 mRNAs were quantified at the
late E stage, when FECH mRNA expression was highest. At
this stage of differentiation, the normal FECH mRNA in
ASO-treated cells from subjects A and B had increased by
59% and 98%, respectively, in comparison with mock-
treated cells (Table 3). FECH mRNA in V1-treated cells of
subject A remained 50% lower than in those of control
subject C. This could have been due to the type of the mu-
tations for subject A: a 1 bp deletion introducing a prema-
ture STOP codon potentially leading to a null allele. FECH
expression could have been improved primarily because of
the redirection of splicing but also because of an overall
improvement in heme biosynthesis. Indeed, ALAS2, en-
coding the key regulator of erythroid heme biosynthesis,
was overexpressed in V1-treated cells when compared
with mock-treated cells at the same stage of differentiation
(48% and 74% improvement for subjects A and B, respec-
tively; Table 3), probably leading to increased ALAS2
activity. ALAS2 expression is also posttranscriptionally
regulated by the IRE/IRP system, and in a situation where
iron is normally available, we expect the ALAS2 mRNA
translation not to be repressed. In the cells of EPP subjects
who were treated with the V1 morpholino, we observed a
cumulative reduction in the amount of PPIX as erythroid
differentiation progressed and culminated at the late E
end-point stage (44% and 58% reduction for subjects A
and B, respectively; Figure 4). Remarkably, PPIX accumula-
tion decreased in the cultured progenitor cells of overt EPP
subjects A and B to a level similar to that found in the
asymptomatic subject D, although the amount of PPIX
remained higher than in the normal subject C (Figure 4).
This result was in agreement with the observation that
the total amount of erythrocyte PPIX that was measured
in peripheral RBCs from asymptomatic EPP subjects wasInt E Late E
c EPP subject
 subject
Int E Late E
Figure 4. Correction of PPIX Over-
production in Developing Primary Eryth-
roblasts of EPP Subjects: Erythroid
Differentiation of CD34þ Cells Isolated
from Peripheral Whole Blood in the Pres-
ence of 45 mM FITC-Labeled V1 or Mock
Morpholinos
Total mononuclear cells were isolated from
whole peripheral blood (60 ml) by Ficoll
density-gradient centrifugation (lympho-
cyte separation medium; PAA Labora-
tories), and CD34þ cells were purified
immunomagnetically by positive selection
(MACS CD34 MicroBead Kit; Miltenyi Bio-
tec). CD34þ cells were cultured in Iscove
Dulbecco’s modified Eagle medium (Invi-
trogen) containing 15% BIT 9500 (Stem-
Cell Technologies), 100 ng/ml stem cell
factor, 2 U/ml erythropoietin, 10 ng/ml
interleukin-6, and 10 ng/ml interleukin-3
ides were added before the induction of heme production at the
centration (45 mM) until mature cells were obtained. Time kinetic
four stages of differentiation: CFU E, pro E, int E, and late E, and
(MFI) values of the accumulated PPIX to MFI of FITC-positive cells
e healthy control subject (subject C), and one asymptomatic EPP
or PMO-mock (squares).
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Figure 5. Erythrocyte Protoporphyrin IX in 40 EPP-Affected
Families
Total erythrocyte PPIX was measured in 40 EPP-affected families,
each having one overt EPP subject, one asymptomatic EPP subject,
and one healthy subject. The results were expressed as a histogram
showing the mean and standard deviation. Means were compared
with the ‘‘t’’ test with Prism 4. Total erythrocyte PPIX level was
2.5-fold higher in peripheral RBCs from asymptomatic EPP
subjects than in healthy subjects.2.5-fold higher than in healthy subjects; however, this
value remained at subclinical levels (Figure 5). It is thus
possible that the reduced amount of PPIX observed in
erythroid cells of affected individuals could become suffi-
ciently low to suppress skin sensitivity in vivo.
Our study is a proof-of-concept for the ability of ASO
therapy to restore normal exon 3–4 pre-mRNA splicing
and increase normal FECH mRNA production while
decreasing PPIX accumulation to a subclinical level in
cultured erythropoietic cells from EPP subjects, and it
opens a new field in treating EPP. The correction of
FECH exon 3–4 splicing is an attractive therapeutic
approach for EPP because the 315-48C allele is present in
more than 90% of overt EPP subjects. Moreover, a modest
increase in FECH activity is sufficient to shift the subject’s
status from overt to asymptomatic.8 In contrast to integra-
tive gene therapy, antisense therapy has several advan-
tages. (1) Because the correction occurs in medullar
erythroblasts and persists in circulating erythrocytes with
a lifespan of about 120 days, the effects of the oligonucle-
otide treatment are probably prolonged; (2) the splicing
correction occurs in the endogenous gene that is tran-
scribed in its physiological environment, thus preventing
excessive or inappropriate expression; and (3) a pharmaco-
logical treatment is easier to administer than somatic gene
therapy and can easily be interrupted in the case of adverse
effects. Targeting pre-mRNA splicing as a therapeutic strat-
egy in Mendelian disorders was proposed several years ago
for Duchenne muscular dystrophy,21 spinal muscular
atrophy22 and b-thalassemia (MIM 613985). In 1993,
Dominski et al. demonstrated that correct splicing can
be restored in vitro by an ASO targeting the b-globin pre-616 The American Journal of Human Genetics 94, 611–617, April 3, 2mRNA.23 Two laboratories were later able to improve
hemoglobin synthesis in vivo and to reduce cell damage
in humanized IVS2–654 thalassemic mice by using either
a morpholino oligomer conjugated to a peptide or an
antisense RNA vector.24,25 The challenge facing antisense
therapeutic strategies is to develop efficient ways to target
ASO to specific cells, in our case to the erythroid pro-
genitors. For systemic administration, it is important to
enhance the specificity of the treatment while reducing
the concentration of ASOs so as to limit toxicity.Different
strategies, including cell-penetrating peptides, aptamers,
and cationic liposome-ASO complexes, have aimed to
enhance ASO targeting. For erythropoietic protoporphyria
therapy, an interesting target could be transferrin receptor
1 (CD71), which is expressed at a very high level during
the differentiation stage, when FECH incorporates iron
into PPIX to form heme. Several peptides and aptamers
that bind with high affinity to human CD71 and display
endocytotic properties are already available,26,27 sug-
gesting that this or similar compounds should be tested
in a humanizedmouse model of EPP and that it might sub-
sequently hold promise in the treatment of individuals
with EPP.Supplemental Data
The Supplemental Data include four figures and two tables and
can be found with this article online at http://www.cell.com/ajhg.Acknowledgments
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